向MYC靶向疗法迈出一大步

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-04-05 DOI:10.1016/j.trecan.2024.03.009

Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher

{"title":"向MYC靶向疗法迈出一大步","authors":"Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher","doi":"10.1016/j.trecan.2024.03.009","DOIUrl":null,"url":null,"abstract":"<p>The <em>MYC</em> proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by <span>Garralda <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg> of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"9 1","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A big step for MYC-targeted therapies\",\"authors\":\"Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher\",\"doi\":\"10.1016/j.trecan.2024.03.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The <em>MYC</em> proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by <span>Garralda <em>et al.</em></span><svg aria-label=\\\"Opens in new window\\\" focusable=\\\"false\\\" height=\\\"8px\\\" viewbox=\\\"0 0 8 8\\\" width=\\\"8px\\\"><path d=\\\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\\\"></path></svg> of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.</p>\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.03.009\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.03.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

MYC 原癌基因编码一种主转录调节因子，在人类癌症中经常发生失调。数十年的努力都未能找到 MYC 靶向治疗药物，这仍然被认为是药物开发的圣杯。我们重点介绍 Garralda 等人最近关于 OMO-103 在实体瘤恶性肿瘤患者中的 1 期临床试验的报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A big step for MYC-targeted therapies

The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.